Gilead, Ar­cus’ PhII gas­troe­sophageal can­cer da­ta ar­gue for TIG­IT an­ti­body drug class po­ten­tial

Gilead and part­ner Ar­cus Bio­sciences’ an­ti-TIG­IT-based reg­i­men has shown ear­ly signs of ef­fi­ca­cy in a small group of gas­troe­sophageal can­cer pa­tients in a mid-stage tri­al, mark­ing a po­ten­tial up­lift for the TIG­IT field af­ter a track record of set­backs.

The Phase II EDGE-Gas­tric tri­al is eval­u­at­ing dif­fer­ent com­bi­na­tions of dom­vanal­imab plus Ar­cus’ an­ti-PD-1 an­ti­body zim­bere­limab and stan­dard-of-care chemother­a­py in cer­tain types of gas­troe­sophageal can­cer. Dom­vanal­imab is a mon­o­clon­al an­ti­body that blocks the TIG­IT pro­tein re­cep­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER